Literature DB >> 2184505

Fluconazole and other azoles: translation of in vitro activity to in vivo and clinical efficacy.

P F Troke1, R J Andrews, G W Pye, K Richardson.   

Abstract

Fluconazole is polar, soluble in water, and metabolically stable and exhibits low protein binding. In contrast, other systemic azoles are lipophilic, metabolically vulnerable compounds with high protein binding and negligible solubility in water. The physical and pharmacokinetic properties of these drugs plus their inherent antifungal potency determine their efficacy. Although fluconazole is less active than ketoconazole in vitro, its distribution throughout the body and the high levels of free drug reached in the blood contribute to and are of value in predicting its efficacy. Even for ketoconazole the levels of free drug in blood may be indicative of efficacy. For very lipophilic agents (itraconazole), blood levels of drug are very low, and organ levels may correlate better with efficacy, although tissue binding will be high and total drug levels in an organ may be misleading indicators of efficacy. The excellent efficacy of fluconazole in vivo despite its low activity in vitro has caused confusion. Consequently, a disk test is being developed to assess whether fungal isolates are sensitive to therapeutically achievable levels of drug.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2184505     DOI: 10.1093/clinids/12.supplement_3.s276

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  13 in total

Review 1.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery.

Authors:  Dennis A Smith; Li Di; Edward H Kerns
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

2.  Testing susceptibility of fungi to fluconazole.

Authors:  M Scheven
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

3.  In vitro and in vivo antifungal activities of TAK-456, a novel oral triazole with a broad antifungal spectrum.

Authors:  Noboru Tsuchimori; Ryogo Hayashi; Naomi Kitamoto; Kentaro Asai; Tomoyuki Kitazaki; Yuji Iizawa; Katsumi Itoh; Kenji Okonogi
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

4.  Effect of prolonged fluconazole treatment on Candida albicans in diffusion chambers implanted into mice.

Authors:  Peter G Sohnle; Beth L Hahn
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

5.  Attenuated virulence of chitin-deficient mutants of Candida albicans.

Authors:  C E Bulawa; D W Miller; L K Henry; J M Becker
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

Review 6.  Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis.

Authors:  C M Perry; R Whittington; D McTavish
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

7.  Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients.

Authors:  M E Ellis; H Clink; P Ernst; M A Halim; A Padmos; D Spence; M Kalin; S M Hussain Qadri; J Burnie; W Greer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-01       Impact factor: 3.267

8.  Mixed oropharyngeal candidiasis due to Candida albicans and non-albicans Candida strains in HIV-infected patients.

Authors:  F Dronda; M Alonso-Sanz; F Laguna; F Chaves; J V Martínez-Suárez; J L Rodríguez-Tudela; A González-López; E Valencia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-06       Impact factor: 3.267

9.  Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans.

Authors:  E W van Etten; N E van de Rhee; K M van Kampen; I A Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 10.  Equine Pulmonary Cryptococcosis: A Comparative Literature Review and Evaluation of Fluconazole Monotherapy.

Authors:  C J Secombe; G D Lester; M B Krockenberger
Journal:  Mycopathologia       Date:  2016-09-21       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.